Handling antineoplastic drugs: how to optimize operator safety without compromising clinical efficiency
The management of antineoplastic and cytotoxic drugs represents one of the highest-risk activities within hospital facilities. Prolonged occupational exposure to these substances, which are recognized for their mutagenic, teratogenic, and carcinogenic properties, requires the strict adoption of operating standards aimed at eliminating environmental contamination and the risk of inhalation or skin contact for healthcare workers.
The handling of these active ingredients is structured into distinct phases involving different hospital figures and departments:
● Preparation and dilution: carried out mainly in hospital pharmacies by pharmacists, to bring the drug from the commercial product to the correct concentration for use through the addition of appropriate solvents;
● Administration: managed by nurses within oncology wards.
Ensuring the highest levels of biosafety throughout this workflow, however, must not result in an increased bureaucratic or operational burden.
Anefficient organization of the workflow, combined with the use of suitable transfer technologies, allows for the combination of operator protection with the timeliness of preparation and administration of oncology therapy.
La European Directive 2010/32/EU establishes the obligation to prevent sharps’ injuries in the healthcare sector. In the context of handling chemotherapeutic agents, prevention extends to protection from aerosols, vapors, and accidental micro-leaks at every stage of the operational cycle.
To meet these protection requirements, the ISO 80369 international standard regulates connection systems such as the Luer Lock, designed to ensure compatibility between devices from different manufacturers, prevent accidental disconnections, and reduce leaks in intravenous infusion, blood sampling, or administration systems.
When advanced protection from hazardous substances is required, the adoption of CSTD (Closed System Transfer Devices) represents a fundamental best practice: these systems mechanically prevent both the ingress of environmental contaminants into the circuit and the escape of drugs or vapors to the outside, protecting healthcare personnel while ensuring the integrity of the preparation.
RISK MAP: CRITICAL PHASES OF THE PROCESS
To understand where and why it is important to apply advanced safety standards and closed-system technologies, it is necessary to analyze the path the drug takes within the healthcare facility.
The journey of the oncology drug, from its receipt to its infusion to the patient, is divided into four well-defined operational phases. Each of these steps involves different professional figures and presents specific technical criticalities that, if not managed correctly, can expose operators to aerosols, micro-spills, or accidental disconnections.
| Operational Phase | Operational Environment | Personnel Involved | Main Technical Criticalities |
| Preparation and reconstitution | Centralized Cytotoxic Preparation Unit (CCPU) / Hospital Pharmacy | Pharmacists, Pharmacy Technicians | Aerosol formation, overpressure in vials, micro-spills from puncturing. |
| Dilution | Centralized Cytotoxic Preparation Unit (CCPU) | Pharmacists, Pharmacy Technicians | Leaks during the transfer of doses into infusion bags, material compatibility. |
| Internal Transport | Hospital Logistics / Wards | Support Personnel, Nurses | Risk of container breakage, accidental disconnection of sets. |
| Administration | Oncology Ward / Day Hospital / Intensive Care Unit | Clinical Nurses | Exposure during line connection/disconnection, leaks during bolus injection or infusion. |
CONTAINMENT METHODOLOGIES: CLOSED-SYSTEM TRANSFER DEVICES (CSTDS)
To prevent the unintended dispersion of cytotoxic substances into the work environment, international guidelines recommend the adoption of closed-system transfer devices, known as CSTDs (Closed System Transfer Devices).
An effective CSTD system mechanically prevents the transfer of environmental contaminants into the system and the escape of hazardous drugs or their vapors to the outside. Key technical requirements specified by NIOSH (National Institute for Occupational Safety and Health) standards include:
- Leak-tight integrity during connection and disconnection: elimination of residual dripping risks on external connector surfaces;
- Absence of exposed sharp parts: integration of passive safety mechanisms to eliminate accidental needlesticks;
- Linear and non-tortuous flow path: prevention of internal turbulence and maintenance of circuit patency even with high-viscosity solutions;
- Extended chemical compatibility: structural resistance of the polymer material in contact with aggressive active ingredients, including organic solvents and taxanes.
BALANCING ERGONOMICS AND OPERATIONAL EFFICIENCY
The introduction of strict safety protocols must not slow down preparation times in hospital pharmacies, where daily preparation volumes are high. An optimal handling system must integrate advanced ergonomic features to promote fluid maneuvers:
1. Ease of grip and maneuverability
Continuous use of double protective gloves reduces tactile sensitivity for operators. Devices should feature surfaces with ergonomic knurling or anchoring wings to facilitate grip and the application of tightening torque without causing hand fatigue.
2. Visual and audible safety feedback
When locking connections between syringes, spikes, and bags, snapping engagement mechanisms (for example an audible "click") provides the operator with immediate confirmation of a leak-tight seal, eliminating operational uncertainties and reducing visual inspection times.
3. Standardization of fittings (Standard Luer Lock)
In accordance with the ISO 80369 international standard, the use of universal Luer Lock fittings and dynamic closure systems ensures seamless interoperability between different equipment used in oncology wards and pharmacies, avoiding the use of additional adapters.
4. Evaluation of dead space and residual volumes
Residual volume is the amount of drug that remains trapped in the connectors at the end of the infusion. When this value is high, two problems occur: the waste of high-cost active ingredients and the risk of hazardous substance dripping during disconnection. Reducing the circuit's "dead space" guarantees a dual benefit: administering the full dose to the patient and protecting operators from accidental dispersion.
BEST PRACTICES FOR CLINICAL RISK REDUCTION
The management of antineoplastic drugs requires a constant balance between therapeutic timeliness, procedural accuracy and maximum protection for operators. To optimize workflow within inpatient wards and Centralized Cytotoxic Preparation Units, field experience and safety standards suggest specific operational measures that make a difference in clinical risk prevention:
- Preliminary visual inspection: verify the structural integrity of components and protective systems before starting handling phases, preventing micro-leaks and accidental contamination;
- Standardization of preparation sequences: maintain a uniform workflow for vial puncturing, volume decompression, and powder reconstitution, reducing procedural variability and errors related to operational fatigue;
- Flow verification and component transparency: prefer devices with high visual clarity to immediately identify air bubbles or precipitates prior to transferring the drug to the ward;
- Protection and flushing of infusion lines: adopt pre-filled administration lines and perform flushingflushingwith a neutral solution prior to introducing the cytotoxic drug, ensuring the absence of free chemical residues in subsequent phases;
- Continuous training on disconnection maneuvers: organize regular training sessions on correct device disconnection techniques at the end of infusion, eliminating risks of sudden traction and accidental dispersion of aerosols or droplets.
Protecting healthcare workers engaged in handling antineoplastic drugs is an essential element of quality care in oncology. Through the choice of suitable technologies, strict compliance with preventive regulations, and careful organization of workflows, it is possible to achieve an excellent balance between maximum occupational health protection, management cost containment, and timely delivery of patient care.
